https://pubmed.ncbi.nlm.nih.gov/38114196

This audit of a large clinical cohort found a very low rate of evolution into rheumatoid arthritis or inflammatory arthritis in patients receiving anti-IL-5 therapy for severe asthma, challenging the idea that anti-IL-5 biologics may be triggering RA.